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The amino acid sequence of a region on chromosomal protein HMG-I from human cells that is phosphorylated by casein kinase II has been deter- 
mined. The sequence is: Leu-Glu-Lys-Glu-Glu-Glu-Glu-Gly-Ile-Ser-Gln-Glu-Ser(P)-Ser(P)-Glu-Glu-Glu-Gln. It corresponds to the C-terminal 
residues 90-107 of HMG-I [(1989) Mol. Cell. Biol. 9,21142123]. Sequence analysis of the native peptide (g&107) after treatment, which specifically 
converts phosphoserine residues to S-ethylcysteine, revealed that 7&80% of serine residues 102 and 103 were phosphorylated in vivo. Both residues 
were fully phosphorylated in vitro by incubation with casein kinase II. These results suggest hat casein kinase II is involved in the regulation 
of HMG-I function in the cells. 
High-mobility-group rotein; Casein kinase II; Protein phosphorylation; Phosphopeptide; Chromatin 
1. INTRODUCTION 
The high-mobility-group protein HMG-I is a 
nonhistone chromosomal phosphoprotein which is ex- 
pressed at high levels in undifferentiated proliferating 
cells and which decreases in quantity when the cells dif- 
ferentiate terminally [ 1,2]. The phosphorylation level 
of this DNA-binding protein changes according to the 
stage of cell cycle being at its maximum at metaphase 
[3]. HMG-I and its isoform HMG-Y probably play an 
important role in cell division and may be involved in 
the condensation of A-T-rich regions of mammalian 
chromosomes and/or in maintaining the undifferen- 
tiated state of chromatin [2,4,5]. 
Casein kinase II (CK-II) is a ubiquitous, highly con- 
served, serineithreonine protein kinase found in the 
cytoplasm and nucleus of eukaryotic cells (see [6]). In- 
creasing evidence suggests that CK-II plays a major role 
in signal transduction between extracellular mitogens 
and nuclear responses [6-91. It is intriguing that a 
number of nuclear phosphoproteins implicated in cell 
proliferation, e.g. myc, myb, fos, EIA, and large T an- 
tigen, all possess potential CK-II phosphorylation sites 
and that myc, myb and large T antigen have been 
shown to be phosphorylated by CK-II in vitro [lO,ll]. 
We have previously shown that HMG-Y is 
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phosphorylated in murine cells and that HMG-I(Y) 
from human and murine cells is not a preferred 
substrate for cyclic nucleotide dependent protein 
kinases or protein kinase C in vitro [12,13]. Since 
phosphorylation appears to be a major mechanism 
used by the cell to reversibly modify the activity of pro- 
teins, identification of kinases which phosphorylate 
HMG-I may contribute to our understanding of how 
HMG-I is regulated. In this study we have analyzed 
HMG-I purified from human cells as a potential 
substrate for nuclear casein kinase II. 
2. MATERIALS AND METHODS 
2.1. Materials 
[y-32P]ATP (3 CVmmol) was purchased from Amersham 
(England). Kemptide was obtained from Serva (Heidelberg, FRG) 
and a synthetic peptide substrate specific for CK-II from Peninsula 
Laboratories (Belmont, CA, USA). HPLC columns and reagents for 
polyacrylamide gel electrophoresis were from Bio-Rad Laboratories 
(Richmond, CA, USA). The low-molecular-weight marker kit was 
purchased from Pharmacia (Uppsala, Sweden). 
2.2. Purification of HMG-I 
HMG-I was purified to homogeneity from 5% perchloric acid ex- 
tracts of full-term human placentae using reversed-phase HPLC on 
a Bio-Rad RP-304 (C4) column with a water/acetonitrile gradient 
(7-20%) containing 0.1% (v/v) trifluoroacetic acid (TFA) [ 141. The 
purity of HMG-I, which eluted at 14.8% acetonitrile, was checked by 
acetic acid/urea and SDS polyacrylamide slab gel electrophoresis 
(15,161. 
2.3. Purification of casein kinase II 
Casein kinase II (nuclear protein kinase II) was partially purified 
from isolated rat liver chromatin using a modification of the pro- 
cedure of Inoue et al. [17]. The 0.4 M NaCl-extract of chromatin was 
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processed as previously described by Palvimo et al. 1121. The specific 
activity of the enzyme assayed with the synthetic peptide substrate 
specific for CK-II (1.3 mM RRREEETEEE in the standard assay 
mixture) was 55 nmol of phosphate/min per mg at 30°C. CK-II did 
not phosphorylate Kemptide (LRRASLG). 
2.4. Phosphorylation of HMG-I and analysis of proteins 
The assay mixture contained 40 mM Tris-Cl, pH 7.5, 0.1 mM 
[Y-‘~P]ATP (200-400 cpm/pmol), 9 mM MgC12, 140 mM NaCl, 
2 mM 2-mercaptoethanol and 5% (v/v) glycerol, 17 pM HMG-I and 
1.8 pgiml CK-II. HMG-I was not dephosphorylated before 
phospho~lation assay. Reactions were initiated by adding radioac- 
tive ATP and terminated by adding concentrated sample buffer and 
analyzed by polya~~lamide gel electrophoresis. For quantification, 
the bands corresponding to HMG-I were cut out after brief staining- 
destaining, solubilized overnight and counted for radioactivity [13]. 
Phosphoamino acid analysis and tryptic peptide mapping of the 
phosphorylated protein were performed as previously described [13]. 
Protein was digested with thermolysin, fractionated by HPLC, and 
peptides were sequenced as in 121. Phosphoserine residues were con- 
verted to S-ethylcysteine by p-elimination and addition of ethanethiol 
according to the procedure of Meyer et al. [IS] as modified by 
Holmes [19]. 
3. RESULTS 
HMG-I purified from human placentae was in- 
vestigated as a potential substrate for CK-II. HMG-I 
was efficiently phosphorylated with a low concentra- 
tion of the kinase. About one mol of [32P]phosphate 
was incorporated per mol of HMG-I in 90 min (fig.1). 
The autoradiograms of acetic acid/urea- and SDS- 
polyacrylamide gels showed a single radioactive band 
comigrating with the Coomassie-stained protein band. 
Under the same conditions, 32P-incorporation to 
HMG-14 was only about 1% of that to HMG-I (not 
shown). Serine was the only amino acid residue 
phosphorylated in HMG-I (fig.2A). Two-dimensional 
tryptic peptide map of the phosphorylated HMG-I 
revealed two major and two minor phosphopeptides 
0 30 60 90 
time (min) 
(fig.2B). When the phosphorylated HMG-I was 
digested with thermolysin and the peptides were 
separated on a C18-column, two radioactive peaks 
eluting close to each other were observed (fig.3). 
Automatic Edman degradation of the major radioac- 
tive peak yielded the sequence shown in fig.4. The 
glutamic acid-rich phosphopeptide reported here is 
located at the C-terminal end of HMG-I (residues 
90-107) [5]. 
The fact that the serine residues of the peptide eluted 
almost exclusively (95%) as phenylthiohydantoin- 
dithiothreitol-dehydroalanine (PTH-DTT-dehydro- 
alanine) adducts at cycles 13 and 14 indicates the 
presence of phosphorylated serines in those positions. 
97% of the phosphoserine standard (Sigma) eluted as a 
PTH-DTT-dehydroalanine adduct in our system, 
whereas a ratio of 43 :57 (PTH-serine to PTH-DTT- 
dehydroalanine adduct) was found in the case of 
serine-5 of unmodified Kemptide-peptide and un- 
phosphorylated serine residues of various peptides, as 
well as serine-99 of the major CK-II phosphorylated 
peptide (90-107). Interestingly, the other radioactive 
peak eluting immediately before the major peak, which 
contained 40% of total radioactivity, also gave the 
same sequence. This peak probably represents apeptide 
in which serine-99, in addition to serine-102 and 
serine-103, was phosphorylated. Thus, the heterogenei- 
ty detected in CK-II specific peptides of HMG-I in two- 
dimensional phosphopeptide analysis is probably due 
to the presence of peptide variants containing different 
combinations of phosphorylations at the three poten- 
tial serine residues (fig.2B). 
Since the labeled peptides contained three serine 
residues and, in our experiments, 32P-incorporation 
was only about 1 mol phosphate per mol HMG-I, we 
investigated the presence of endogenous phosphates at 
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Fig.], Phosphorylation of purified HMG-I from human placentae by casein kinase II from rat liver chromatin. The reactions were run as described 
in section 2. SDS-polyacrylamide (15Vo) gel electrophoretic analysis of the labeled proteins with low-molecular-weight marker proteins is shown 
on the right. 
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Fig.2. Phosphoamino acid analysis (A) and tw~~mensio~al peptide map (B) of 32P-labeled HMG-I. HMG-I was phospho~iated by CK-II for 
80 min. The hydrolysate of phosphorylated protein (6 M HCI, ilO”C, 2 h) was analyzed by thin-layer high-voltage lectrophoresis (HVE) at pH 
1.9 (2 kV, 45 min) and autoradiography (A). Tryptic phosphopeptides were separated on cellulose thin layer sheets using HVE at pH 3.5 (1 kV, 
30 min) in the first dimension and ascending chromatography (37.5% n-butanol, 25% pyridine, 7.5% acetic acid, 30% HrO) in the second 
dimension followed by autoradiography (B). 
those positions. Without in vitro phosphorylation, 
88% and 85% of the serine residues at cycles 13 and 14 
eluted as their PTH-DTT-dehydroalanine adducts, 
whereas the respective value was only 57% at cycle 10. 
The presence of phosphoserines at positions 13 and 14 
was confirmed by sequencing the same peptide after 
modification with ethanethio1, which specifically 
modifies phosphoserine to S-ethylcysteine. PTH-S- 
ethylcysteine, eluting just before diphenylthiourea [18], 
was present at cycles 13 and 14, but not at cycle 10. We 
interpret the data to indicate that HMG-I from human 
placenta contained without in vitro phosphorylation 
about 0.7 mol phosphate at serine-102 and 0.8 mol 
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Fig.3. Separation of ‘“P-labeled peptides generated by digestion of Fig.4. Sequence analysis of the major therm&tic phosphopeptide of 
HMG-I with thermolysin on a Bio-Rad RP-318 column using a HMG-I phosphorylated by CK-II. Yields of amino acids identified in 
0-7O(rlo linear acetonitrile gradient containing 0.1% TFA in 60 min. cycles are plotted vs cycle number. The peptide was sequenced using 
The fractions (30 s/OS ml) were counted for radioactivity as an Applied Biosystems 477A sequencer connected to 120A (on-line) 
Cerenkov radiation. PTH-amino acid analyzer. 
phosphate at serine-103 per mol of the CK-II-preferred 
peptide. After an 80 min incubation with CK-II, both 
serines were fully phosphorylated to 1 mol/mol and 
serine-99 to 0.3 mol/mol. 
4. DISCUSSION 
The sequence of human HMG-I cDNA has been 
recently reported [S] . The cDNA encodes a protein con- 
taining 107 amino acids whose sequence is virtually 
identical to the amino acid sequence of human placen- 
tal HMG-I determined by peptide fragment sequencing 
160- 
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(201. The protein designated as HMG-Y has an amino 
acid sequence identical to that of HMG-I except for an 
internal deletion of 1 l-amino acids [1,5]. HMG-I(Y) 
structure appears to be well-conserved during evolu- 
tion; the deduced amino acid sequence similarity bet- 
ween murine and human HMG-I(Y) is 97% [IS]. 
According to our results, HMG-I contains en- 
dogenous phosphates at serine residues 102 and 103, 
which are also pbosphorylated in vitro by casein kinase 
II. The consensus sequence of casein kinase II 
substrates consists of a serine or threonine followed by 
a cluster of glutamic and/or aspartic acid residues, the 
residue at position + 3 playing a crucial role [Zl]. Addi- 
tionally, phosphoserine residues can replace carboxylic 
acid residues as specificity determinants [22]. 
Serine-102 and serine-103 fuifil the above criteria as 
well as serine-99, if serine-102 is phospho~lated. 
Current data suggest hat CK-II, which is released 
from chromatin at an ionic strength required to 
dissociate HMG proteins from chromatin, 
phosphorylates HMG-I and probably also HMG-Y in 
vivo and is thus involved in the regulation of function 
of these proteins. The addition of a negative charge to 
HMG-I(Y) (the net charge of this region, i.e. residues 
90-107, is -8 without phosphorylation and -14, if 
fully phosphorylated) may strengthen the interaction 
between the highly acidic G-terminal tail of HMG-I(Y) 
and the basic histones and take part in condensa- 
tion/repression of chromosomal structures during 
mitosis. We have previously shown that phosphoryla- 
tion of HMG-14, which is also a basic protein with a 
highIy asymmetrical charge distribution, at its acidic C- 
terminal region increases considerably its binding af- 
finity for histone Hl [23]. The CK-II-mediated 
phosphorylation of HMG-I may represent one of the 
targets of the circuitry involved in mitogenic signal 
transduction and may act in concert with some 
phosphorylated nuclear proto-oncogene products like 
c-myc which is also present at high levels in undifferen- 
tiated cells and which decreases in quantity when the 
cells differentiate terminally [ 10,i 1,241. 
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